New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
11:57 EDTAMAT, RPRX, BSBR, CTICHigh option volume stocks; AMAT RPRX BSBR CTIC
News For AMAT;RPRX;BSBR;CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
14:00 EDTRPRXRepros Therapeutics volatility elevated as shares trade near two-year low
Repros Therapeutics overall option implied volatility of 158 is above its 26-week average of 93 according to Track Data, suggesting large price movement.
October 22, 2014
06:12 EDTAMATKLA-Tencor removed from Focus List at Citigroup
Subscribe for More Information
October 21, 2014
18:36 EDTRPRXOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTRPRXRepros Therapeutics: Results from Androxal study exhibit positive safety profile
Repros Therapeutics reported results from a large, controlled, long-term safety study comparing Androxal to a placebo. In this study of Androxal, ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. The last patient completed this study in late September. The Company's planned NDA will include study ZA-303, which will provide a significant portion of the support of long-term safety by providing data from 141 subjects exposed for one year or more. Over 200 subjects reached this milestone in the entire exposure database. ICH guidance for drugs to treat non-life-threatening conditions suggests that a minimum of 100 subjects should be exposed to the drug for one year.
October 17, 2014
09:17 EDTRPRXOn The Fly: Pre-market Movers
Subscribe for More Information
October 16, 2014
20:03 EDTRPRXRepros Therapeutics upcoming meeting with FDA to be Type C, not Type B
Subscribe for More Information
07:54 EDTAMATApplied Materials weakness creates buying opportunity, says Stifel
Stifel believes that Applied Materials' (AMAT) fundamental story has not changed, while the weakness in the shares is an overreaction to certain issues, including the Microchip (MCHP) preannouncement. Stifel expects the company to benefit from strong WFE spending in 2015 and increasing capital intensity trends in the chip sector. The firm keeps a $25 price target and Buy rating on the shares.
07:41 EDTRPRXRepros Therapeutics management to meet with Brean Capital
Subscribe for More Information
October 15, 2014
10:02 EDTAMATOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:39 EDTAMATApplied Materials upgraded at BofA/Merrill
Subscribe for More Information
06:15 EDTAMATApplied Materials upgraded to Buy from Neutral at BofA/Merrill
06:08 EDTAMATApplied Materials implied volatility of 47 at upper end of index mean range
Subscribe for More Information
October 13, 2014
12:33 EDTRPRXOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use